Video Experimental Relacionado

Updated: Jan 13, 2026

Validation of Therapeutic Agent Conjugation to Polyvinyl Alcohol-Coated Medical Devices

Validation of Therapeutic Agent Conjugation to Polyvinyl Alcohol-Coated Medical Devices

Published on: November 29, 2024

Perspectivas prácticas sobre bioexenciones de resistencia adicional para formas farmacéuticas sólidas orales:

Chandra Teja Uppuluri¹, Adithya Karthik Bhattiprolu¹, Anuj Kumar Saini^1,2

¹Biopharmaceutics Group, Global Clinical Management, Integrated Product Development Organization (IPDO), Dr. Reddy's Laboratories Ltd., Hyderabad, India.

Xenobiotica; the fate of foreign compounds in biological systems

|January 6, 2026

Resumen

Las bioexenciones de resistencia adicional agilizan el desarrollo farmacéutico al evitar estudios de bioequivalencia (BE) separados para múltiples concentraciones de fármacos. Esta revisión analiza las expectativas regulatorias globales y los esfuerzos de armonización para formas de dosificación de liberación inmediata y modificada.

Área de la Ciencia:

Ciencias Farmacéuticas
Asuntos Regulatorios
Desarrollo de Fármacos

Sus antecedentes:

Las bioexenciones de resistencia adicional permiten la aprobación regulatoria de múltiples concentraciones de fármacos sin estudios individuales de bioequivalencia (BE).
Esta estrategia ofrece ventajas significativas en el desarrollo farmacéutico y el acceso al mercado.
Comprender los paisajes regulatorios actuales es crucial para una implementación exitosa.

Objetivo del estudio:

Proporcionar un análisis exhaustivo de las expectativas regulatorias actuales para las bioexenciones de resistencia adicional.
Examinar las directrices de las principales agencias reguladoras, incluidas la FDA de EE. UU., la EMA, HC y la ANVISA.
Explorar el impacto de las directrices ICH M13A y M13B (borrador) en el desarrollo farmacéutico global.

Principales métodos:

Revisión de las directrices regulatorias actuales y la literatura científica.
Análisis de criterios científicos clave: linealidad farmacocinética, proporcionalidad de formulación y similitud de disolución.
Examen de las interpretaciones específicas de la agencia y ejemplos de casos hipotéticos.

Principales resultados:

Existen diferencias significativas en las expectativas regulatorias para las bioexenciones en diferentes jurisdicciones.
Los esfuerzos de armonización en el marco de las directrices ICH M13 tienen como objetivo simplificar las presentaciones globales.
Los matices específicos del producto y los requisitos regionales influyen críticamente en la elegibilidad de la bioexención.

Conclusiones:

Las bioexenciones de resistencia adicional son una herramienta valiosa para el desarrollo eficiente de fármacos multimarca.
Alinear las estrategias con las directrices existentes y emergentes es esencial para el cumplimiento normativo.
Las perspectivas prácticas de los ejemplos de casos ayudan a navegar por complejos escenarios de bioexención.

Palabras clave:

bioexenciones de resistencia adicional directrices ICH M13 formulaciones de liberación inmediata y modificada similitud de disolución proporcionalidad de formulación requisitos reglamentarios

Más Videos Relacionados

A Package of Established Analytical Tools to Investigate the Solid-State Alteration of Lipid-Based Excipients

A Package of Established Analytical Tools to Investigate the Solid-State Alteration of Lipid-Based Excipients

Published on: August 9, 2022

Solubility of Hydrophobic Compounds in Aqueous Solution Using Combinations of Self-assembling Peptide and Amino Acid

Solubility of Hydrophobic Compounds in Aqueous Solution Using Combinations of Self-assembling Peptide and Amino Acid

Published on: September 20, 2017

Videos de Conceptos Relacionados

Bioequivalence studies: Biowaivers

Bioequivalence studies: Biowaivers

Body:In certain scenarios, in vitro dissolution tests can replace in vivo bioequivalence studies. This is particularly true when a drug product, though available in varying strengths, maintains proportional similarity in its active and inactive ingredients. In such cases, the need for in vivo bioequivalence studies for lower strength variants may be waived, provided dissolution tests and in vivo studies on the highest strength yield satisfactory results.Bioequivalence can be indicated through...

Biopharmaceutical Factors Influencing Drug Product Design: Overview

Biopharmaceutical Factors Influencing Drug Product Design: Overview

Rational drug product design integrates knowledge of the drug’s physicochemical properties, formulation components, manufacturing techniques, and intended route of administration. Each factor influences the drug’s performance, including how it is released, absorbed, and eliminated in the body.The physicochemical properties of a drug—such as solubility, stability, and particle size—affect its compatibility with excipients and the choice of dosage form. Excipients, though...

Pharmaceutical Alternatives: Polymorphic Form-Related and Particle Size-Related Therapeutic Nonequivalence

Pharmaceutical Alternatives: Polymorphic Form-Related and Particle Size-Related Therapeutic Nonequivalence

Changes in polymorphic forms can significantly influence the bioavailability of poorly soluble drugs. Although the FDA defines pharmaceutical equivalence based on having the same active ingredient, dosage form, and route of administration, it does not automatically disqualify products with different polymorphic forms. This means two products with different polymorphs can still be deemed pharmaceutically equivalent. However, polymorphic differences can affect properties like wettability,...

Drug Products: Biologics, Biosimilars and Interchangeables

Drug Products: Biologics, Biosimilars and Interchangeables

Body:Biologics, derived from living sources such as humans, animals, or microorganisms, represent a significant category of pharmaceuticals. These complex molecules, developed through advanced biotechnological methods or purified from natural sources, include essential medical treatments like insulin and growth hormones. The complexity of biologics arises from their large molecular structures and the intricate processes required for their production, making them distinct from conventional...

Formulation and Manufacturing Process: Physical Attributes of Generic Tablets and Capsules

Formulation and Manufacturing Process: Physical Attributes of Generic Tablets and Capsules

Bioequivalence in generic drugs, such as tablets and capsules, refers to their pharmaceutical equivalence to the brand-name counterparts. However, for therapeutic equivalence, manufacturers must also consider physical attributes like size, shape, and weight (FDA Guidance for Industry, December 2003). Discrepancies in these aspects could impact patient compliance and cause medication errors. For instance, swallowing difficulties, often experienced with larger tablets or capsules, can lead to...

Factors Influencing Drug Absorption: Pharmaceutical Parameters

Factors Influencing Drug Absorption: Pharmaceutical Parameters

Solid dosage forms such as tablets and capsules undergo rigorous manufacturing processes to ensure stability and effectiveness. Their dissolution and absorption properties are influenced significantly by the choice of excipients (inactive ingredients that serve various roles in the formulation), and the methodology applied during production. The manufacturing parameters, such as compression force and granulation techniques, significantly affect dissolution rates. Elevated compression forces...